NanoVibronix completes pilot phase of UroShield study at University of Michigan

NanoVibronix (NAOV) announced the successful completion of the first phase of a Randomized Control Trial study of UroShield by researchers at the University of Michigan UM.This first phase of the trial is a precursor to the full study by researchers at UM. It was conducted primarily with nursing home residents and was aimed at studying the impact of UroShield( on improving patient’s quality of life by its potential to reduce urinary tract infections, catheter blockages and pain caused by the long-term use of urinary catheters. Brian Murphy, Chief Executive Officer of the Company, commented, “The first phase of the study served as a validation pilot in advance of a full study. With this phase now complete, researchers at UM can advance to the next phase, a full Randomized Control Trial of additional patients. We expect the full trial to commence in 2025.” …Dr. Lona Mody, Professor of Internal Medicine at the University of Michigan, commented, “Our team has achieved the goals of this pilot phase, including refining our recruitment and retention strategies, delivering the intervention and developing data collection tools. We look forward to the next phase.”